Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma
The prognostic value of serum CA-125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CAP) or cyclophosphamide, doxor...
Gespeichert in:
| Veröffentlicht in: | Acta obstetricia et gynecologica Scandinavica 1994-09, Vol.73 (8), p.658-662 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 662 |
|---|---|
| container_issue | 8 |
| container_start_page | 658 |
| container_title | Acta obstetricia et gynecologica Scandinavica |
| container_volume | 73 |
| creator | Ron, Ilan-Gil Inbar, Moshe Gelernter, Ilana Lewysohn, Orly Ayalon, Daniel Dale, Janet Chaitchik, Samario |
| description | The prognostic value of serum CA-125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CAP) or cyclophosphamide, doxorubicin and cisplatinum (CAP). Patients with serum CA-125 values below the normal value of 35 U/ml after two courses had a significantly longer median survival (p |
| doi_str_mv | 10.3109/00016349409013462 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_00016349409013462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AOG1483</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4623-9a42775648e21519197d4bd945618d6d5981dd582fb550b1ea6878ebb16862e53</originalsourceid><addsrcrecordid>eNqFkEtvEzEUhS0EKmnhB7BA8oLtgD1-i1UUlVCpoqqYCnbWnbFHcZmX7ElK_z0eJcoGCVaWfc53r89B6B0lHxkl5hMhhErGDSeGUMZl-QKtqCSkIJyWL9Fq0YvF8BpdpvSYb6Xi-gJdKMOpMWyF4CF5PLZ4sy5oKXD0aRqH_DSPeIrehWbGaR8P4QAdniBC72cf00JMMAc_zAk_hXmHwR1gaLzD4wFigAE3EJswjD28Qa9a6JJ_ezqv0MOX62rztbi9295s1rdFk__NCgO8VEpIrn1JBTXUKMdrZ7iQVDvphNHUOaHLthaC1NSD1Er7uqZSy9ILdoXocW4Tx5Sib-0UQw_x2VJil7bsX21l5v2RmfZ1792ZONWT9Q8nHVIDXRtzxpDONsYIV9JkmzzankLnn_-_167vtpTrZX5xBEOa_e8zCPGXlYopYX9829r7n1V1X32v7JLx88k_tGPsYeehm3e5am8fx30ccr__SPsHEdihbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Ron, Ilan-Gil ; Inbar, Moshe ; Gelernter, Ilana ; Lewysohn, Orly ; Ayalon, Daniel ; Dale, Janet ; Chaitchik, Samario</creator><creatorcontrib>Ron, Ilan-Gil ; Inbar, Moshe ; Gelernter, Ilana ; Lewysohn, Orly ; Ayalon, Daniel ; Dale, Janet ; Chaitchik, Samario</creatorcontrib><description>The prognostic value of serum CA-125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CAP) or cyclophosphamide, doxorubicin and cisplatinum (CAP). Patients with serum CA-125 values below the normal value of 35 U/ml after two courses had a significantly longer median survival (p <0.0001) and longer disease-free survival (p = 0.007) than did those patients whose CA-125 levels dropped to normal after the third or a later course of chemotherapy. A response in CA-125 levels after the first two courses of chemotherapy may indicate which patients should continue with the current chemotherapy regimen and which patients should he ol'fered salvage therapy.</description><identifier>ISSN: 0001-6349</identifier><identifier>EISSN: 1600-0412</identifier><identifier>DOI: 10.3109/00016349409013462</identifier><identifier>PMID: 7941993</identifier><identifier>CODEN: AOGSAE</identifier><language>eng</language><publisher>Oxford, UK: Informa UK Ltd</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - immunology ; Adenocarcinoma - pathology ; Adult ; advanced ovarian carcinoma ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; CA-125 Antigen - immunology ; CA-125 serum level ; chemotherapy ; Cisplatin - therapeutic use ; Cyclophosphamide - therapeutic use ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Middle Aged ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - immunology ; Ovarian Neoplasms - pathology ; Prognosis ; Tumors</subject><ispartof>Acta obstetricia et gynecologica Scandinavica, 1994-09, Vol.73 (8), p.658-662</ispartof><rights>1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1994</rights><rights>1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4623-9a42775648e21519197d4bd945618d6d5981dd582fb550b1ea6878ebb16862e53</citedby><cites>FETCH-LOGICAL-c4623-9a42775648e21519197d4bd945618d6d5981dd582fb550b1ea6878ebb16862e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.3109%2F00016349409013462$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.3109%2F00016349409013462$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3304769$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7941993$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ron, Ilan-Gil</creatorcontrib><creatorcontrib>Inbar, Moshe</creatorcontrib><creatorcontrib>Gelernter, Ilana</creatorcontrib><creatorcontrib>Lewysohn, Orly</creatorcontrib><creatorcontrib>Ayalon, Daniel</creatorcontrib><creatorcontrib>Dale, Janet</creatorcontrib><creatorcontrib>Chaitchik, Samario</creatorcontrib><title>Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma</title><title>Acta obstetricia et gynecologica Scandinavica</title><addtitle>Acta Obstet Gynecol Scand</addtitle><description>The prognostic value of serum CA-125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CAP) or cyclophosphamide, doxorubicin and cisplatinum (CAP). Patients with serum CA-125 values below the normal value of 35 U/ml after two courses had a significantly longer median survival (p <0.0001) and longer disease-free survival (p = 0.007) than did those patients whose CA-125 levels dropped to normal after the third or a later course of chemotherapy. A response in CA-125 levels after the first two courses of chemotherapy may indicate which patients should continue with the current chemotherapy regimen and which patients should he ol'fered salvage therapy.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>advanced ovarian carcinoma</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>CA-125 Antigen - immunology</subject><subject>CA-125 serum level</subject><subject>chemotherapy</subject><subject>Cisplatin - therapeutic use</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - immunology</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Prognosis</subject><subject>Tumors</subject><issn>0001-6349</issn><issn>1600-0412</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtvEzEUhS0EKmnhB7BA8oLtgD1-i1UUlVCpoqqYCnbWnbFHcZmX7ElK_z0eJcoGCVaWfc53r89B6B0lHxkl5hMhhErGDSeGUMZl-QKtqCSkIJyWL9Fq0YvF8BpdpvSYb6Xi-gJdKMOpMWyF4CF5PLZ4sy5oKXD0aRqH_DSPeIrehWbGaR8P4QAdniBC72cf00JMMAc_zAk_hXmHwR1gaLzD4wFigAE3EJswjD28Qa9a6JJ_ezqv0MOX62rztbi9295s1rdFk__NCgO8VEpIrn1JBTXUKMdrZ7iQVDvphNHUOaHLthaC1NSD1Er7uqZSy9ILdoXocW4Tx5Sib-0UQw_x2VJil7bsX21l5v2RmfZ1792ZONWT9Q8nHVIDXRtzxpDONsYIV9JkmzzankLnn_-_167vtpTrZX5xBEOa_e8zCPGXlYopYX9829r7n1V1X32v7JLx88k_tGPsYeehm3e5am8fx30ccr__SPsHEdihbA</recordid><startdate>199409</startdate><enddate>199409</enddate><creator>Ron, Ilan-Gil</creator><creator>Inbar, Moshe</creator><creator>Gelernter, Ilana</creator><creator>Lewysohn, Orly</creator><creator>Ayalon, Daniel</creator><creator>Dale, Janet</creator><creator>Chaitchik, Samario</creator><general>Informa UK Ltd</general><general>Blackwell Publishing Ltd</general><general>Taylor & Francis</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199409</creationdate><title>Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma</title><author>Ron, Ilan-Gil ; Inbar, Moshe ; Gelernter, Ilana ; Lewysohn, Orly ; Ayalon, Daniel ; Dale, Janet ; Chaitchik, Samario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4623-9a42775648e21519197d4bd945618d6d5981dd582fb550b1ea6878ebb16862e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>advanced ovarian carcinoma</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>CA-125 Antigen - immunology</topic><topic>CA-125 serum level</topic><topic>chemotherapy</topic><topic>Cisplatin - therapeutic use</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - immunology</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Prognosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ron, Ilan-Gil</creatorcontrib><creatorcontrib>Inbar, Moshe</creatorcontrib><creatorcontrib>Gelernter, Ilana</creatorcontrib><creatorcontrib>Lewysohn, Orly</creatorcontrib><creatorcontrib>Ayalon, Daniel</creatorcontrib><creatorcontrib>Dale, Janet</creatorcontrib><creatorcontrib>Chaitchik, Samario</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ron, Ilan-Gil</au><au>Inbar, Moshe</au><au>Gelernter, Ilana</au><au>Lewysohn, Orly</au><au>Ayalon, Daniel</au><au>Dale, Janet</au><au>Chaitchik, Samario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma</atitle><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle><addtitle>Acta Obstet Gynecol Scand</addtitle><date>1994-09</date><risdate>1994</risdate><volume>73</volume><issue>8</issue><spage>658</spage><epage>662</epage><pages>658-662</pages><issn>0001-6349</issn><eissn>1600-0412</eissn><coden>AOGSAE</coden><abstract>The prognostic value of serum CA-125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CAP) or cyclophosphamide, doxorubicin and cisplatinum (CAP). Patients with serum CA-125 values below the normal value of 35 U/ml after two courses had a significantly longer median survival (p <0.0001) and longer disease-free survival (p = 0.007) than did those patients whose CA-125 levels dropped to normal after the third or a later course of chemotherapy. A response in CA-125 levels after the first two courses of chemotherapy may indicate which patients should continue with the current chemotherapy regimen and which patients should he ol'fered salvage therapy.</abstract><cop>Oxford, UK</cop><pub>Informa UK Ltd</pub><pmid>7941993</pmid><doi>10.3109/00016349409013462</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6349 |
| ispartof | Acta obstetricia et gynecologica Scandinavica, 1994-09, Vol.73 (8), p.658-662 |
| issn | 0001-6349 1600-0412 |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_00016349409013462 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - immunology Adenocarcinoma - pathology Adult advanced ovarian carcinoma Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences CA-125 Antigen - immunology CA-125 serum level chemotherapy Cisplatin - therapeutic use Cyclophosphamide - therapeutic use Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Ovarian Neoplasms - drug therapy Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology Prognosis Tumors |
| title | Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A31%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20CA-125%20response%20to%20predict%20survival%20parameters%20of%20patients%20with%20advanced%20ovarian%20carcinoma&rft.jtitle=Acta%20obstetricia%20et%20gynecologica%20Scandinavica&rft.au=Ron,%20Ilan-Gil&rft.date=1994-09&rft.volume=73&rft.issue=8&rft.spage=658&rft.epage=662&rft.pages=658-662&rft.issn=0001-6349&rft.eissn=1600-0412&rft.coden=AOGSAE&rft_id=info:doi/10.3109/00016349409013462&rft_dat=%3Cwiley_cross%3EAOG1483%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/7941993&rfr_iscdi=true |